WASHINGTON -- (BUSINESS WIRE) -- The Biotechnology Industry Organization (BIO) today announces plenary sessions, Business Roundtables and Therapeutic Workshops selected for the 15th annual BIO CEO & Investor Conference. Moderators and panelists chosen to speak represent former White House Chiefs of Staff, industry thought leaders, academics and biopharma executives. The conference, to be held in New York City, February 11 – 12, 2013, is the largest independent investor conference focused on publicly-traded biotechnology companies.
“With more than 600 investors and 150 presenting companies planning to attend, the BIO CEO & Investor Conference serves a vital role in bringing industry leaders together and generating the investment interest that will help bring new therapies to market,” said Alan Eisenberg, BIO’s Executive Vice President of Emerging Companies and Business Development. “This year's program features over 50 thought leaders who will draw from their unparalleled experience in the industry to share their candid insights on what 2013 and beyond will bring.”
The BIO CEO & Investor Conference plenary sessions will forecast both the year ahead in biotech and the political outlook for the next four years. The Business Roundtables will focus on reimbursement, successfully navigating the Chinese market, biopharma collaborations and alternative venues to public markets. Therapeutic Workshops will address topics the treatment pipeline for pancreatic cancer, chronic lymphocytic leukemia and rare diseases.
Plenary sessions include:
Opening Plenary: Word
on the Street: The Buy-Side View for 2013
Monday, February 11th, 12:00 pm - 12:55 pm
Moderator: Mark Schoenebaum, MD, Senior Managing Director and Head, Healthcare Research, ISI Group
Closing Plenary: Tales
From the Wild West (Wing): Reflections from White House Chiefs of Staff
Tuesday, February 12th, 4:00 pm – 4:55 pm
Moderator: James C. Greenwood, President & CEO, BIO
Business Roundtables include:
Show Me the Money: Reimbursement in an ACA World
Monday, February 11th, 9:00 am – 9:55 am
Moderator: Roger Longman, Chief Executive Officer, Real Endpoints
the Other Half Lives: What’s Happening in Venture and Why it Matters
Monday, February 11th, 2:00 pm – 2:55 pm
Moderator: Jeffrey Baumel, Partner, SNR Denton
Companies Thinking Big – China Tactical Strategies
Monday, February 11th, 3:30 pm – 4:25 pm
Moderator: Jimmy Zhang, PhD, MBA, Managing Director, MSD Early Investments--Greater China, Merck & Co. Inc.
a Ring on It – When Drug Development Partnerships Become Acquisitions
Tuesday, February 12th, 12:00 pm – 12:55 pm
Moderator: Jeff Stewart, Senior Engagement Manager, Campbell Alliance
Road Less Traveled: Alternative Avenues to Public Markets
Tuesday, February 12th, 1:30 pm – 2:25 pm
Moderator: William Hicks, Member, Mintz Levin
Therapeutic Workshops include:
Oncology: Panning for Gold – Prospecting the Pancreatic Pipeline
Monday, February 11th, 10:30 am – 11:25 am
Moderator: Brian Klein, MD, Vice President & Senior Biotechnology Analyst, Stifel Nicolaus
Drugs: Making Rare Diseases Rarer
Tuesday, February 12th, 9:00 am – 9:55 am
Moderator: Ritu S. Baral, Principal, Sr. Analyst – Biotechnology Equity Research, Canaccord Genuity
The CLL Chronicles – The Next Chapter in Clinical Developments
Tuesday, February 12th, 12:00 pm – 12:55 pm
Moderator: Joel Sendek, Managing Director & Biotechnology Analyst, Stifel Nicolaus & Company
Additionally, the event will feature the BIO One-on-One Partnering™ system which provides the opportunity to arrange meetings between investors, companies and industry executives. Furthermore, the event features presentations from more than 150 leading biotechnology and pharmaceutical companies.
Qualified institutional and venture investors whose primary activity is direct investment in research and development companies are eligible for complimentary registration. Equity research analysts from investment banking institutions also qualify as investors. Media registration is complimentary for credentialed members of the media. All registrations are subject to verification of credentials.
BIO is pleased to recognize the leadership provided by the BIO CEO & Investor Conference sponsors. The supporting bank sponsors include: Stifel Nicolaus & Company, Leerink Swann and ROTH Capital Partners, LLC.
To learn more about the BIO CEO & Investor Conference, including registration and program information, please visit here.
BIO represents more than 1,100 biotechnology companies, academic institutions, state biotechnology centers and related organizations across the United States and in more than 30 other nations. BIO members are involved in the research and development of innovative healthcare, agricultural, industrial and environmental biotechnology products. BIO also produces the BIO International Convention, the world’s largest gathering of the biotechnology industry, along with industry-leading investor and partnering meetings held around the world. BIO produces BIOtechNOW, an online portal and monthly newsletter chronicling “innovations transforming our world.” Subscribe to BIOtechNOW.
Upcoming BIO Events
CEO & Investor Conference
February 11 – 12, 2013
New York City, NY
March 25-27, 2013
San Diego, CA
April 22 – 25, 2013
Congress on Industrial Biotechnology
June 16-19, 2013